Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply

Lancet Gastroenterol Hepatol. 2021 Sep;6(9):688. doi: 10.1016/S2468-1253(21)00253-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biological Products* / adverse effects
  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Mesalamine

Substances

  • Biological Products
  • Mesalamine